Clinical Trial Investor

The Science VK2809 is a thyroid hormone receptor agonist that possesses selectivity for liver tissue, it is currently being developed by Viking Therapeutics for the treatment of metabolic disorders, including non-alcoholic steatohepatitis (NASH). Non-alcoholic fatty liver disease (NAFLD) is a condition in which excess fat is stored in your liver, it is an emerging global health problem and is a risk factor for Type 2 Diabetes and Cardiovascular Disease. Nonalcoholic steatohepatitis (NASH) is an advanced form of NAFLD in which you have inflammation and cell damage in the liver (Hepatitis), it is a predisposing factor for the development of cirrhosis and liver cancer. The development of NASH is very complicated, as seen in the figure above. Environmental, metabolic and genetic factors contribute to the development and progression of NASH by affecting diverse organs such as the liver, the intestine, and adipose tissue. In particular, excess caloric intake increases fre

The Science Ruxolitinib is a Janus-associated Kinase inhibitor with selectivity for JAK1 and JAK2 proteins, these are proteins that regulate the number of blood cells the body makes.  It has been developed and marketed by Incyte Corporation for the treatment of Myelofibrosis (Bone Marrow cancer) and a condition called Polycythemia Vera (uncontrolled production of blood cells). However it is currently undergoing investigation for the treatment of graft versus host disease (GVHD) in patients following bone marrow transplant. GVHD accounts for almost a third of deaths associated with bone marrow transplants. For patients with GVHD, there is almost no standard treatment, with currents treatments showing limited activity and response rates of 20-40%. There is a clear unmet need for a novel active treatment for GVHD. Patients with cancers that affect the blood or lymph nodes will often have bone marrow transplants as part of their treatment. Malignant cells need to be removed and d